CD44 and hepatocellular carcinoma: Research indicates that imatinib mesylate cubes (HA-IM-CBs) can stimulate the CD44-regulated caspase-mediated mitochondrial apoptosis pathway, thereby resisting the activity of HCC (Lai et al., 2022a; Nisha et al., 2022; Sun et al., 2019).